Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 8
Submit an article Journal homepage
319
Views
10
CrossRef citations to date
0
Altmetric
Theme: Breast Cancer - Review

The classification of invasive carcinoma of the breast

Louisa M Gannon Medical student, Health Sciences Building, University College, Dublin 4, Ireland; Medical student, Health Sciences Building, University College, Dublin 4, Ireland
,
Maura B Cotter Senior House Officer, Department of Histopathology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland; Senior House Officer, Department of Histopathology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland
&
Cecily M Quinn Consultant Histopathologist, Irish National Breast Screening Programme & Department of Histopathology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland. [email protected]; Consultant Histopathologist, Irish National Breast Screening Programme & Department of Histopathology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland. [email protected]
Pages 941-954 | Published online: 10 Jan 2014

References

  • Sobin LH, Gospodarowicz MK, Wittekind C (Eds). TNM Classification of Malignant Tumours (7th Edition). American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC), Wiley-Blackwell, Oxford, UK (2009).
  • Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (Eds). WHO Classification of Tumours of the Breast (4th Edition), Volume 4. International Agency for Research on Cancer, Lyon, France (2012).
  • Pathology Reporting of Breast Disease. A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme’s Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists’ Minimum Dataset for Breast Cancer Histopathology. NHSBSP Publication No 58 (2005).
  • Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 11, 359–377 (1957).
  • Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403–410 (1991).
  • Rakha EA, El-Sayed ME, Lee AH et al. Prognostic significance of Nottingham histological grade in invasive breast carcinoma. J. Clin. Oncol. 26(19), 3153–3158 (2008).
  • Rakha EA, Reis-Filho JS, Baehner F et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 12(4), 207 (2010).
  • Blamey RW, Pinder SE, Ball GR et al. Reading the prognosis of the individual with breast cancer. Eur. J. Cancer 43(10), 1545–1547 (2007).
  • Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19(4), 980–991 (2001).
  • Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50(4), 409–417 (2007).
  • Ellis IO, Coleman D, Wells C et al. Impact of a national external quality assessment scheme for breast pathology in the UK. J. Clin. Pathol. 59(2), 138–145 (2006).
  • Cabioglu N, Ozmen V, Kaya H et al. Increased lymph node positivity in multifocal and multicentric breast cancer. J. Am. Coll. Surg. 208(1), 67–74 (2009).
  • Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63(1), 181–187 (1989).
  • Tot T. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections. Cancer 110(11), 2551–2560 (2007).
  • Grabau D, Jensen MB, Rank F, Blichert-Toft M. Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival. APMIS 115(7), 828–837 (2007).
  • Pugliese M, Stempel M, Patil S et al. The clinical impact and outcomes of Immunohistochemistry-only metastasis in breast cancer. Am. J. Surg. 200(3), 368–373 (2010).
  • Weaver DL, Ashikaga T, Krag DN et al. Effect of occult metastases on survival in node-negative breast cancer. N. Engl. J. Med. 364(5), 412–421 (2011).
  • Vinh-Hung V, Nguyen NP, Cserni G et al. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 5(10), 1585–1603 (2009).
  • Mansel RE, Fallowfield L, Kissin M et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J. Natl. Cancer Inst. 98(9), 599–609 (2006). Erratum in: J. Natl. Cancer Inst. 98(12), 876 (2006).
  • Hayes BD, Feeley L, Quinn CM et al. Axillary fine needle aspiration cytology for pre-operative staging of patients with screen-detected invasive breast carcinoma. J. Clin. Pathol. 64(4), 338–342 (2011).
  • Douglas-Jones AG, Woods V. Molecular assessment of sentinel lymph node in breast cancer management. Histopathology 55(1), 107–113 (2009).
  • Krag DN, Anderson SJ, Julian TB et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised Phase 3 trial. Lancet Oncol. 11(10), 927–933 (2010).
  • Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6), 569–575 (2011).
  • Galimberti V, Cole BF, Zurrida S et al; International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a Phase 3 randomised controlled trial. Lancet Oncol. 14(4), 297–305 (2013).
  • Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118–145 (2007).
  • Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28(16), 2784–2795 (2010).
  • Bartlett JM, Ibrahim M, Jasani B et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J. Clin. Pathol. 60, 816–819 (2007).
  • Goulding H, Pinder S, Cannon P et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum. Pathol. 26(3), 291–294 (1995).
  • Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11(2), 155–168 (1998).
  • Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17(5), 1474–1481 (1999).
  • Epstein M, Me Y, Press MF. ERBB2 testing: assessment status for targeted therapies. In: Diseases of the Breast (4th Edition). Harris JR, Lippman ME, Morrow M et al (Eds). Wolters Kluwer Lippincott Williams & Wilkins Publishers, PA, USA 431–442 (2010).
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich J, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177–182 (1987).
  • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783–792 (2001).
  • Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J. Mammary Gland Biol. Neoplasia 14(1), 55–66 (2009).
  • Bartlett JM, Starczynski J, Atkey N et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridization methods. J. Clin. Pathol. 64(8), 649–653 (2011).
  • Perez EA, Dueck AC, McCullough AE et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2 positivity criteria. J. Natl. Cancer Inst. 104(2), 159–162 (2012).
  • Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol. 182(3), 311–322 (2000).
  • Trihia H, Murray S, Price K et al. Ki-67 expression in breast carcinoma: association with grading system, clinical parameters and other prognostic factors – a surrogate marker. Cancer 97, 1321–1331 (2003).
  • Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol. 61, 689–696 (2008).
  • Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29(32), 4273–4278 (2011).
  • Aleskandarany MA, Green AR, Benhasouna AA et al. Prognostic value of proliferation assay in the luminal, HER2-positive and triple negative biologic classes of breast cancer. Breast Cancer Res. 14(1), R3 (2012).
  • Dowsett M, Nielsen TO, A’Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J. Natl. Cancer Inst. 103(22), 1656–1664 (2011).
  • Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 101(10), 736–750 (2009).
  • Eroles P, Bosch A, Perez-Fidalgo A, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev. 38, 698–707 (2012).
  • Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature 15(8), 907–915 (2009).
  • Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
  • Van’t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
  • Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 98, 10869–10874 (2001).
  • Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263–280 (2010).
  • Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 16(21), 5222–5232 (2010).
  • Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 22(8), 1736–1747 (2011).
  • Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol. 23(29), 7350–7360 (2005).
  • Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25(10), 1239–1246 (2007).
  • Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009).
  • Parker JS, Mullins M, Cheang M et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27(8), 1160–1167 (2009).
  • Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367–5374 (2004).
  • Keam B, Im S-A, Lee K-H et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 13, R22 (2011).
  • Popovska S, Ooi A, Ivanov IN, Ivanova NG, Dineva TB. Triple-negative breast cancer does not fully overlap with ‘basal-like’ molecular profile – a morphological and immunohistochemical study. J. Biomed. Clin. Res. 3(1), 45–50 (2010).
  • Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750–2767 (2011).
  • Anders CK, Winer EP, Ford JM et al. Poly (ADP-ribose) polymerase inhibition: ‘Targeted’ therapy for triple-negative breast cancer. Clin. Cancer Res. 16(19), 4702–4710 (2010).
  • Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology 25(11), 1014–1025 (2011).
  • Kummar S, Chen A, Parchment RE et al. Advances in using PARP inhibitors to treat cancer. BMC Med. 10, 25 (2012).
  • Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin. Breast Cancer 10(Suppl. 1), E23–E31 (2010).
  • Wehland M, Bauer J, Infanger M, Grimm D. Target-based anti-angiogenic therapy in breast cancer. Curr. Pharm. Des. 18(27), 4244–4257 (2012).
  • Koboldt DC, Fulton RS, McLellan MD et al. Comprehensive molecular portraits of human breast tumours. The Cancer Genome Atlas Network. Nature 490(7418), 61–70 (2012).
  • Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403), 400–404 (2012).
  • Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv. Anat. Pathol. 16(4), 204–215 (2009).
  • Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication and prediction. Lancet 378, 1812–1823 (2011).
  • Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamixofen treated, node negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
  • Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor positive breast cancer. J. Clin. Oncol. 24(23), 3726–3734 (2006).
  • Cardoso F, Piccart-Gebhart M, Van’t Veer L, Rutgers E. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol. Oncol. 1, 246–251 (2007).
  • Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart M. Clinical application of the 70-gene profile: The MINDACT trial. J. Clin. Oncol. 26(5), 729–735 (2008).
  • Natrajan R, Lambros MB, Geyer FC et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes. Chromosomes Cancer 48(4), 351–365 (2009).
  • Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J. Natl. Cancer Inst. 97(13), 966–975 (2005).
  • Robertson FM, Bondy M, Yang W et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J. Clin. 60(6), 351–375 (2010).
  • Cristofanilli M. Novel targeted therapies in inflammatory breast cancer. Cancer 116(11 Suppl.), 2837–2839 (2010).
  • Dawood S, Ueno NT, Valero V et al. Differences in survival among women with stage III inflammatory and non-inflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9), 1819–1826 (2011).
  • Tuma RS. ALK gene amplified in most inflammatory breast cancers. J. Natl. Cancer Inst. 104(2), 87–88 (2012).
  • Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20(6), 479–489 (1992).
  • Sarrio D, Perez-Mies B, Hardisson D et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23(19), 3272–3283 (2004).
  • Orvieto E, Maiorano E, Bottiglieri L et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 113(7), 1511–1520 (2008).
  • Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216(2), 141–150 (2008).
  • Loo LW, Grove DI, Williams EM et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 64(23), 8541–8549 (2004).
  • Simpson PT, Reis-Filho JS, Lambros MB et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J. Pathol. 215(3), 231–244 (2008).
  • Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 6(3), R149–R156 (2004).
  • Pestalozzi BC, Zahrieh D, Mallon E et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J. Clin. Oncol. 26(18), 3006–3014 (2008).
  • Buchanan CL, Flynn LW, Murray MP et al. Is pleomorphic lobular carcinoma really a distinct clinical entity? J. Surg. Oncol. 98(5), 314–317 (2008).
  • Fedko MG, Scow JS, Shah SS et al. Pure tubular carcinoma and axillary nodal metastases. Ann. Surg. Oncol. 17(Suppl. 3), 338–342 (2010).
  • Rakha EA, Lee AH, Evans AJ et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J. Clin. Oncol. 28(1), 99–104 (2010).
  • Javid SH, Smith BL, Mayer E et al. Tubular carcinoma of the breast: results of a large contemporary series. Am. J. Surg. 197(5), 674–677 (2009).
  • Jacquemier J, Reis-Filho JS, Lakhani SR, Rakha E. Carcinomas with medullary features. In: WHO Classification of Tumours of the Breast (4th Edition), Volume 4. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (Eds). International Agency for Research on Cancer, Lyon, France 46–47 (2012).
  • Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: a population-based perspective. Med. Oncol. 28(3), 783–744 (2011).
  • Bertucci F, Finetti P, Cervera N et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 66(9), 4636–4644 (2006).
  • Eisinger F, Jacquemier J, Charpin C et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 58(8), 1588–1592 (1998).
  • Lakhani SR, Gusterson BA, Jacquemier J et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin. Cancer Res. 6(3), 782–789 (2000).
  • Rody A, Holtrich U, Pusztai L et al. T-cell metagene predicts a favourable prognosis in estrogen receptor-negative and HER2 positive breast cancers. Breast Cancer Res. 11(2), R15 (2009).
  • Sabatier R, Finetti P, Cervera N et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res. Treat. 126(2), 407–420 (2011).
  • Liu H, Tan H, Cheng Y, Zhang X, Gu Y, Peng W. Imaging findings in mucinous breast carcinoma and correlating factors. Eur. J. Radiol. 80(3), 706–712 (2011).
  • Tan PH, Tse GM, Bay BH. Mucinous breast lesions: diagnostic challenges. J. Clin. Pathol. 61(1), 11–19 (2008).
  • Capella C, Eusebi V, Mann B, Azzopardi JG. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 4(6), 613–630 (1980).
  • Lacroix-Triki M, Suarez PH, MacKay A et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J. Pathol. 222(3), 282–298 (2010).
  • Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod. Pathol. 14(8), 768–776 (2001).
  • Shin SJ, DeLellis RA, Ying L, Rosen PP. Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am. J. Surg. Pathol. 24(9), 1231–1238 (2000).
  • Weigelt B, Geyer FC, Horlings HM, Kreike B, Halfwerk H, Reis-Filho JS. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod. Pathol. 22(11), 1401–1414 (2009).
  • Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ. Intracystic papillary carcinomas of the breast: a re-evaluation using a panel of myoepithelial cell markers. Am. J. Surg. Pathol. 30, 1002–1007 (2006).
  • Mulligan AM, O’Malley FP. Metaplastic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases. Int. J. Surg. Pathol. 15, 143–147 (2007).
  • Collins L, O’Malley F, Visscher D, Moriya T, Ichihara S, Reis-Filho JS. Encapsulated papillary carcinoma. In: WHO Classification of Tumours of the Breast (4th Edition), Volume 4. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (Eds). International agency for research on cancer, Lyon, France, 106–107 (2012).
  • Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K. The reversed pattern of MUC1 expression is characteristic of invasive micropapillary carcinoma of the breast. Breast Cancer 13(1), 58–63 (2006).
  • Guo X, Chen L, Lang R, Fan Y, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am. J. Clin. Pathol. 126(5), 740–746 (2006).
  • Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44(4), 332–338 (2004).
  • Marchio C, Iravani M, Natrajan R et al. Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J. Pathol. 218(3), 301–315 (2009).
  • Marchio C, Iravani M, Natrajan R et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J. Pathol. 215(4), 398–410 (2008).
  • Reis-Filho JS, Lakhani SR, Gobbi H, Sneige N. Metaplastic carcinoma. In: WHO Classification of Tumours of the Breast (4th Edition), Volume 4. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (Eds). International agency for research on cancer, Lyon, France, 48–49 (2012).
  • Foschini MP, Pizzicannella G, Peterse JL, Eusebi V. Adenomyoepithelioma of the breast associated with low-grade adenosquamous and sarcomatoid carcinomas. Virchows Arch. 427(3), 243–250 (1995).
  • Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am. J. Surg. Pathol. 33(4), 534–541 (2009).
  • Reis-Filho JS, Milanezi F, Carvalho S et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 49(1), 10–21 (2006).
  • Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am. J. Surg. Pathol. 28(11), 1506–1512 (2004).
  • Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J. Pathol. 204(2), 131–139 (2004).
  • Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69(10), 4116–4124 (2009).
  • Gilbert JA, Goetz MP, Reynolds CA et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol. Cancer Ther. 7(4), 944–951 (2008).
  • Jung SY, Kim HY, Nam BH et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res. Treat. 120(3), 627–637 (2010).
  • Podetta M, D’Ambrosio G, Ferrari A et al. Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumour with a favorable clinical outcome. Report of two cases. Tumori 95(2), 264–267 (2009).
  • Honma N, Takubo K, Akiyama F et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 47(2), 195–201 (2005).
  • Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod. Pathol. 23(2), 205–212 (2010).
  • Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 12(4), R54 (2010).
  • Azoulay S, Lae M, Freneaux P et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favourable outcome. Mod. Pathol. 18(12), 1623–1631 (2005).
  • Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor gene in carcinomas of the breast and head and neck. Proc. Natl. Acad. Sci. USA. 106(44), 18740–18744 (2009).
  • Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including «triple negative carcinomas» of low malignant potential. Semin. Diagn. Pathol. 27(1), 77–90 (2010).
  • Marchio C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas). J. Clin. Pathol. 63(3), 220–228 (2010).
  • Shin SJ, Rosen PP. Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. Am. J. Surg. Pathol. 26(4), 413–420 (2002).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.